Impact of S-1 adjuvant chemotherapy longer than 6 months on survival in patients with resected pancreatic cancer: a nationwide survey by the Japan Pancreas Society based on real-world data.
Yoshito TomimaruHidetoshi EguchiYosuke InoueYuichi NagakawaAkihiro OhbaHideki TakamiMichiaki UnnoTomohisa YamamotoShoji KawakatsuTsuyoshi HayashiRyota HiguchiHirohisa KitagawaSatoshi HattoriTsutomu FujiiYoshiki HirookaHisato IgarashiMasayuki KitanoTamotsu KurokiAtsushi MasamuneYasuhiro ShimizuMasaji TaniSatoshi TannoYoshihisa TsujiHiroki YamaueSohei SatoiYoshifumi Takeyamanull nullPublished in: Cancer (2022)
The current findings suggest that extending S-1 adjuvant chemotherapy beyond 6 months has no significant additional effect on survival in patients with PDAC. This could be useful in determining whether to extend S-1 chemotherapy in patients who have completed the standard 6-month treatment.